2018 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis-Reference-Cited by-同舟云学术

2018 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis

Published:2021-03-01 Issue:1 Volume:2 Page:1-14
ISSN:2719-4523
Container-title:Rheumatology and Immunology Research
language:en
Short-container-title:

Author:

Tian Xinping¹,Wang Qian¹,Li Mengtao¹,Zhao Yan¹,Zhang Zhiyi²,Huang Cibo³,Liu Yi⁴,Xu Huji⁵,Chen Yaolong⁶,Wu Lijun⁷,Su Yin⁸,Xiao Weiguo⁹,Zhang Miaojia¹⁰,Zhao Dongbao¹¹,Sun Linyun¹²,Zuo Xiaoxia¹³,Lei Junqiang¹⁴,Li Xiaofeng¹,Zeng Xiaofeng¹

Affiliation:

1. Department of Rheumatology, Peking Union Medical College Hospital (PUMCH) , Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID) , Key Laboratory of Rheumatology and Clinical Immunology , Ministry of Education, Chinese Rheumatism Data Center (CRDC) , Chinese SLE Treatment and Research Group (CSTAR) , Beijing , China

2. Department of Rheumatology , the First Affiliated Hospital Affiliated to Harbin Medical University , Harbin , Heilongjiang Province , China

3. Department of Rheumatology , Beijing Hospital , Beijing , China

4. Department of Rheumatology and Immunology , West China Hospital , Sichuan University , Chengdu , Sichuan Province , China

5. Department of Rheumatology and Immunology , Shanghai Changzheng Hospital , the Second Military Medical University , Shanghai , China

6. Institute of Health Data Science , Lanzhou University , Chinese GRADE Center , Lanzhou , Gansu Province , China

7. Department of Rheumatology , Xinjiang Uygur Autonomous Region People's Hospital , Urumuqi , Xinjiang Uygur Autonomous Region , China

8. Department of Rheumatology , Peking University People's Hospital , Beijing , China

9. Department of Rheumatology , The First Affiliated Hospital of China Medical University , Shenyang , Liaoning Province , China

10. Department of Rheumatology , The First Affiliated Hospital with Nanjing Medical University . Nanjing , JiangSu Province , China

11. Department of Rheumatology and Immunology , Changhai Hospital, The Second Military Medical University/Naval Medical University , Shanghai , China

12. Department of Rheumatology , Nanjing Drum Tower Hospital of Nanjing University Medical School

13. Department of Rheumatology and Immunology , Xiangya Hospital of Central South University , Rheumatic Diseases Research Center of Hunan Province , Changsha , China

14. Department of Radiology , The First Hospital of Lanzhou University , Lanzhou , Gansu Province , China

Abstract

Abstract A multidisciplinary guideline development group was established to formulate this evidence-based diagnosis and treatment guidelines for rheumatoid arthritis (RA) in China. The grading of recommendations, assessment, development, and evaluation (GRADE) system was used to rate the quality of the evidence and the strength of recommendations, which were derived from research articles and guided by the analysis of the benefits and harms as well as patients’ values and preferences. A total of 10 recommendations for the diagnosis and treatment of RA were developed. This new guideline covered the classification criteria, disease activity assessment and monitoring, and the role of disease modifying antirheumatic drugs (DMARDs), biologics, small molecule synthetic targeting drugs, and glucocorticoids in the treat-to-target approach of RA. This guideline is intended to serve as a tool for clinicians and patients to implement decision-making strategies and improve the practices of RA management in China.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.2478/rir-2021-0002/pdf

Reference116 articles.

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid Arthritis. Lancet. 2016;388(10055):2023–2038. doi: 10.1016/S0140-6736(16)30173-8

2. McInnes IB, Schett G. Pathogenetic Insights from the Treatment of Rheumatoid Arthritis. Lancet. 2017;389(10086):2328–2337. doi: 10.1016/S0140-6736(17)31472-1

3. Mcinnes IB, Schett G. The Pathogenesis of Rheumatoid Arthritis. N Engl J Med. 2011;365(23):2205–2219. doi: 10.1056/NEJMra1004965

4. Burmester GR, Pope JE. Novel Treatment Strategies in Rheumatoid Arthritis. Lancet. 2017;389(10086):2338–2348. doi: 10.1016/S0140-6736(17)31491-5

5. Dougados M, Soubrier M, Antunez A, et al. Prevalence of Comorbidities in Rheumatoid Arthritis and Evaluation of Their Monitoring: Results of an International, Cross-Sectional Study (COMORA). Ann Rheum Dis. 2014;73(1):62–68. doi: 10.1136/annrheumdis-2013-204223

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chinese medicine Di-long (Pheretima vulgaris) and its active fraction exhibit anti-rheumatoid arthritis effects by inhibiting CXCL10/CXCR3 chemotaxis in synovium;Journal of Ethnopharmacology;2024-10

2. Application of superb microvascular imaging technology in clinical disease activity of rheumatoid arthritis;Clinical Rheumatology;2024-09-12

3. CD142+ synovial fibroblast drives meniscus destruction in rheumatoid arthritis;2024-09-04

4. Trends and future projections of incidence rate and mortality of rheumatoid arthritis in China: a systematic analysis based on GBD 2021 data;Clinical Rheumatology;2024-07-29

5. Experiences of Chinese Rheumatoid Arthritis Patients Who Chose Western Medicine, Traditional Chinese Medicine, and a Combination of Treatments: A Study Based on Interviews and Thematic Analysis;Patient Preference and Adherence;2024-07